Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + ciprofloxacin + metronidazole
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy consists of the PD-1 checkpoint inhibitor pembrolizumab administered alongside the broad-spectrum antibiotics ciprofloxacin and metronidazole. Developed as an experimental regimen by researchers at NYU Langone Health, it is designed to treat surgically resectable pancreatic adenocarcinoma by modulating the gut and intratumoral microbiome. The rationale is based on preclinical findings that certain bacteria can suppress the immune system's ability to fight tumors; by depleting these bacteria, the regimen aims to enhance the activation of T cells and improve the efficacy of pembrolizumab in the pancreatic tumor microenvironment. In clinical protocols, patients receive a lead-in of antibiotics followed by pembrolizumab doses during the preoperative period.
- Brand names
- KeytrudaCiproFlagyl
- Other names
- Gut Microbiome Modulation with Pembrolizumab and Antibiotics
02
Targets
Topo IV (Bacterial Topoisomerase IV)DNA gyraseKRAS (Kirsten rat sarcoma viral oncogene homolog)PDCD1 (Programmed cell death protein 1 receptor)MAPK3 (Mitogen-activated protein kinase 1)Neuraminidase
Beyond the preview
Go deeper on pembrolizumab + ciprofloxacin + metronidazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + ciprofloxacin + metronidazole.